John Schneider is an Infectious Disease physician. ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5841 S Maryland Ave
Chicago, IL 606371443
Telephone
888-824-0200Registry record last updated 24 Oct 2022.
Clinical trials
- Social Network Diffusion of COVID-19 Prevention for Diverse Criminal Legal Involved Communities
Sponsor: University of Chicago
- Community Network-driven COVID-19 Testing and Vaccination of Vulnerable Populations in the Central US
Sponsor: University of Chicago
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year20255 payments
- ViiV Healthcare CompanyProgram year20254 payments
- Theratechnologies Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
53.8%Protease Inhibitor28%Darunavir50%Ritonavir50%Part D<11 patientsHuman Immunodeficiency Virus Integrase Strand Transfer Inhibitor14%Tivicay100%Part D<11 patients+ 1 more class in this area
Cardiovascular
46.2%Calcium channel blocker18.3%Amlodipine Besylate100%Part D<11 patientsStatin16.1%Atorvastatin Calcium100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
23 NIH research awards on record, funded 2012–2026 per NIH RePORTER. The latest:
- Methodology and Advanced Analytics Resource Center 2.0
University of Chicago
FY2026$2,831,643UM1DA050098 - Heavy cannabis use, neurocognition and PrEP care engagement among young people
University of Chicago
FY2026$818,585R01DA057351 - A Sicangu-driven social network strategy for syphilis prevention
University of Chicago
FY2026$417,567R21AI191042
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Yousef Khader
Jordan University of Science and Technology
Andrew Rambaut
University of Edinburgh
Olayinka Stephen Ilesanmi
University College Hospital
Maysaa El Sayed Zaki
Mansoura University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”